Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting

Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML

67th American Society of Hematology (ASH) Annual Meeting and Exposition

Dec 6, 2025 • 5:30 pm - 7:30 pm EST